An updated FDA review found that the smoking-cessation drug Chantix was associated with higher risk of myocardial infarction, stroke and death compared with placebo, although the difference in risk was not statistically significant. Chantix was also linked to depression and suicidal tendencies, but recent studies showed that the drug did not raise the risk of psychiatric conditions.
FDA review warns of possible cardiovascular risk with Chantix
SmartBrief Job Listings for Health Care
|Vice President - Government Products||
Health Alliance Plan
|Director, Compliance - Health Plan Privacy & Security||
|Chief Medical Officer||
VANDERBILT HEALTH AFFILIATE NETWORK
|Commercial Health Insurance Strategist__Job #52-14||
American Academy of Family Physicians
|Manager of Payer Relations||
Pharmacy Quality Solutions, Inc.